Meeting Banner
Abstract #2904

Prognostic Characterization of Prostate Cancer from Benign Tissue MRS

Leo L. Cheng1, Emily A. Decelle2, Johannes L Kurth2, Shulin Wu3, Taylor L. Fuss2, Lindsey A. Vandergrift2, Elita M. DeFeo2, Elkan F. Halpern2, Matthias L Taupitz2, W. Scott McDougal2, Aria F. Olumi2, and Chin-Lee Wu2

1Molecular Pathology, Massachusetts General Hospital, Charlestown, MA, United States, 2Massachusetts General Hospital, Charlestown, MA, United States, 3Massachusetts General Hospital, Boston, MA, United States

While serum prostate specific antigen (PSA) testing improved early detection of prostate tumors, implementation of this tool also created a large patient population in which identified cancer lesions were actually indolent. For patients who choose to undergo prostatectomy, cancer aggressiveness can only be determined by post-procedure pathology analysis of cancerous tissue. Additionally, cancer recurrence predictions are often unreliable. As an alternative method to aid decisions regarding treatment, we sought to develop MRS tools which can predict cancer aggressiveness based on the novel use of histologically benign (Hb) tissue.

This abstract and the presentation materials are available to members only; a login is required.

Join Here